Katy Rebecca Newton

Katy serves as VP of Process Development at Achilles and has worked in the cell therapy field for over 10 years. She has extensive experience in developing adoptive cell therapy products and managing GMP production. Prior to joining Achilles, she was VP of Process Development at Cell Medica Ltd. where she led the process development and optimisation that enabled the transfer of their first oncology cell product from an academic partner to an external contract manufacturer and subsequent IND filing. Katy holds a PhD in T-cell immunology from University College London (ICH) and a BSc in Biochemistry with applied molecular biology from the University of Manchester (UMIST).